Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alaska Permanent Fund Corp

Alaska Permanent Fund Corp raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 74.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,846 shares of the biopharmaceutical company’s stock after acquiring an additional 1,641 shares during the period. Alaska Permanent Fund Corp’s holdings in Regeneron Pharmaceuticals were worth $3,378,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $26,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $31,000. MCF Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the period. Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $37,000. Finally, Sutton Wealth Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Down 0.1 %

NASDAQ REGN traded down $0.78 on Wednesday, hitting $906.54. 369,717 shares of the stock were exchanged, compared to its average volume of 489,761. Regeneron Pharmaceuticals, Inc. has a 52-week low of $684.80 and a 52-week high of $998.33. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market capitalization of $99.50 billion, a price-to-earnings ratio of 26.17, a P/E/G ratio of 2.59 and a beta of 0.11. The company’s 50-day moving average price is $951.41 and its two-hundred day moving average price is $893.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The business had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same period in the previous year, the company posted $10.96 EPS. Regeneron Pharmaceuticals’s revenue was up .6% on a year-over-year basis. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. BMO Capital Markets increased their target price on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. TD Cowen raised their price objective on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, April 15th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $977.77.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the transaction, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,022 shares of company stock worth $10,552,991. Corporate insiders own 8.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.